Pictet Asset Management
TRVI icon

Pictet Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Pictet Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6M Buy
2,013,786
+307,738
+18% +$4.48M 0.04% 392
2026
Q1 		$20.4M Buy
1,706,048
+174,035
+11% +$1.95M 0.02% 495
2025
Q4 		$19.2M Buy
1,532,013
+1,520,754
+13,507% +$17.6M 0.02% 540
2025
Q3 		$103K Buy
+11,259
New +$84.4K ﹤0.01% 1979

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Pictet Asset Management's TRVI Position: Q2 2026 in Review

Pictet Asset Management increased its Trevi Therapeutics (TRVI) stake by 18% in Q2 2026, buying an estimated $4.48M and bringing the position to 2,013,786 shares worth $37.6M. The position accounts for 0.04% of the portfolio, ranked #392.

Pictet Asset Management first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 69 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Pictet Asset Management held 2,013,786 shares of Trevi Therapeutics worth $37.6M as of Q2 2026.
  • Pictet Asset Management bought 307,738 Trevi Therapeutics shares in Q2 2026, an estimated $4.48M.
  • Trevi Therapeutics made up 0.04% of Pictet Asset Management's portfolio in Q2 2026, its #392 holding.
  • Pictet Asset Management first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 69 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.